問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of General Internal Medicine

Division of Hematology & Oncology

更新時間：2023-09-19

陳彩雲Chen, Tsai-Yun
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 9 個月

  • teresa@mail.ncku.edu.tw

Recruiting Trial

112Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳彩雲

List

170Cases

2014-01-01 - 2021-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2021-10-01 - 2027-12-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2020-12-25 - 2025-07-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2023-01-02 - 2029-06-01

Phase III

Active
Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Mocravimod as Adjunctive and Maintenance Treatment in Adult AML Patients Undergoing Allogeneic HCT

  • Condition/Disease

    Adult Acute Myeloid Leukemia

  • Test Drug

    mocravimod

Participate Sites
4Sites

Recruiting4Sites

2019-08-09 - 2026-12-31

Phase III

Active
A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

  • Condition/Disease

    Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

  • Test Drug

    Ponatinib

Participate Sites
4Sites

Recruiting3Sites

2023-04-01 - 2026-12-31

Phase I

Active
A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ACE1831, an Allogeneic Anti-CD20 Antibody-Conjugated Gamma Delta T-cell Therapy, in Adult Subjects With Relapsed/Refractory CD20-expressing B-cell Malignancies

  • Condition/Disease

    B-cell Lymphoma

  • Test Drug

    靜脈點滴注射劑

Participate Sites
8Sites

Not yet recruiting4Sites

Recruiting4Sites

2014-04-01 - 2018-06-30

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2012-06-01 - 2016-08-15

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2017-03-15 - 2024-12-31

Phase III

Completed
A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Complement Inhibitor-Naïve Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

  • Condition/Disease

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

  • Test Drug

    ALXN1210

Participate Sites
7Sites

Terminated6Sites

2022-04-30 - 2028-09-30

Phase III

Active
A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-314)

  • Condition/Disease

    Chronic Lymphocytic Leukemia

  • Test Drug

    錠劑

Participate Sites
5Sites

Recruiting5Sites

1 4 5 6 7 8 17
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB